The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Improved pathologic complete response rates for triple-negative breast cancer in the I-SPY2 Trial.
 
Douglas Yee
Honoraria - Boehringer Ingelheim
Consulting or Advisory Role - Martell diagnostic
Research Funding - Boehringer Ingelheim
 
Rebecca Arielle Shatsky
Honoraria - Horizon CME; OncoSec; Relevate Health; SOTERIA Precision Medicine; The Dedham Group
Consulting or Advisory Role - OncoSec; SOTERIA Precision Medicine; The Dedham Group
Speakers' Bureau - Horizon CME
Research Funding - CytomX Therapeutics (Inst); Genentech (Inst); Merck (Inst); OncoSec (Inst); Oncternal Therapeutics (Inst); Phoenix Molecular Designs (Inst)
 
Christina Yau
No Relationships to Disclose
 
Denise M. Wolf
No Relationships to Disclose
 
Rita Nanda
Consulting or Advisory Role - AstraZeneca; Cardinal Health; Cardinal Health; Fujifilm; Gilead Sciences; Immunomedics; Infinity Pharmaceuticals; ITeos Therapeutics; Merck; OBI Pharma; OncoSec; Seagen
Research Funding - Arvinas (Inst); AstraZeneca (Inst); Celgene (Inst); Corcept Therapeutics (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Merck (Inst); OBI Pharma (Inst); Odonate Therapeutics (Inst); OncoSec (Inst); Pfizer (Inst); Seagen (Inst); Taiho Oncology (Inst)
Other Relationship - G1 Therapeutics
 
Laura van 't Veer
Employment - Agendia
Stock and Other Ownership Interests - Agendia
 
Donald A. Berry
Other Relationship - Donald Berry is co-owner of Berry Consultants, LLC, a company that designs adaptive Bayesian clinical trials (including I-SPY 2) for pharmaceutical and medical device companies, NIH cooperative groups, patient advocacy groups, and international consortia.
 
Angela DeMichele
Research Funding - Calithera Biosciences (Inst); Genentech (Inst); Novartis (Inst); Pfizer (Inst)
 
Laura Esserman
Consulting or Advisory Role - Blue Cross Blue Shield Association
Research Funding - Merck
Travel, Accommodations, Expenses - Blue Cross Blue Shield Association
(OPTIONAL) Uncompensated Relationships - Quantum Leap Healthcare Collaborative